真实世界两中心队列中未治疗的系统性硬化症相关间质性肺病患者的特征与疾病病程
在386例系统性硬化症相关间质性肺病(SSc-ILD)患者中,74%基线未接受改变病情药物治疗;未治疗患者3年累积进展发生率为39.9%(32.9-46.2),弥漫性皮肤型SSc和广泛肺纤维化独立预测进展,作者认为结果支持改变临床实践中选择治疗患者的做法。
要点
- 386例SSc-ILD中287例(74%)基线未接受ILD改变病情药物治疗。
- 未治疗患者3年累积进展发生率为39.9%(32.9-46.2)。
- 弥漫性皮肤型SSc和广泛肺纤维化独立预测未治疗患者ILD进展。
核心结论
- 约40%的未治疗患者在3年后出现ILD进展,且SSc-ILD已有有效安全的治疗,作者认为结果支持改变临床实践中选择治疗患者的做法。
研究设计与样本
- 在两个特征明确的SSc-ILD队列中描述未治疗患者的疾病特征与病程,接受过潜在ILD改变病情药物者归为治疗组。
主要发现
- 386例SSc-ILD患者中287例(74%)基线未治疗。
- 弥漫性皮肤型SSc和广泛肺纤维化独立预测未治疗患者的ILD进展。
关键数值与推荐
- 未治疗患者ILD进展定义为:FVC较基线下降≥10%;或12±3个月内FVC下降5%-9%且DLCO下降≥15%;或开始任何ILD改变病情治疗;或随访期间ILD范围增加。
临床怎么用
- 作者认为,鉴于约40%的未治疗患者3年后出现ILD进展且已有有效安全的治疗,结果支持改变临床实践中选择治疗患者的做法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). According to expert statements, not all SSc-ILD patients require pharmacological therapy. OBJECTIVES: To describe disease characteristics and disease course in untreated SSc-ILD patients in two well characterised SSc-ILD cohorts. METHODS: Patients were classified as treated if they had received a potential ILD-modifying drug. ILD progression in untreated patients was defined as (1) decline in forced vital capacity (FVC) from baseline of ≥10% or (2) decline in FVC of 5%-9% associated with a decline in diffusing capacity for carbon monoxide (DLCO)≥15% over 12±3 months or (3) start of any ILD-modifying treatment or (4) increase in the ILD extent during follow-up. Multivariable logistic regression was performed to identify factors associated with non-prescription of ILD-modifying treatment at baseline. Prognostic factors for progression in untreated patients were tested by multivariate Cox regression. RESULTS: Of 386 SSc-ILD included patients, 287 (74%) were untreated at baseline. Anticentromere antibodies (OR: 6.75 (2.16-21.14), p=0.001), limited extent of ILD (OR: 2.39 (1.19-4.82), p=0.015), longer disease duration (OR: 1.04 (1.00-1.08), p=0.038) and a higher DLCO (OR: 1.02 (1.01-1.04), p=0.005) were independently associated with no ILD-modifying treatment at baseline. Among 234 untreated patients, the 3 year cumulative incidence of progression was 39.9% (32.9-46.2). Diffuse cutaneous SSc and extensive lung fibrosis independently predicted ILD progression in untreated patients. CONCLUSION: As about 40% of untreated patients show ILD progression after 3 years and effective and safe therapies for SSc-ILD are available, our results support a change in clinical practice in selecting patients for treatment.
引用
- Scheidegger M, Boubaya M, Garaiman A, et al. Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort. RMD Open. 2024. PMID: 38199606. doi:10.1136/rmdopen-2023-003658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。